Development and clinical evaluation of AFP-L3% as a new tumor marker for hepatocellular carcinoma

被引：0
|
作者：
Wang, YY
Kanke, F
Kato, H
Wise, MG
Mallory, TS
Satomura, S
机构：
[1] Wako Pure Chem Ind Ltd, Richmond, VA USA
[2] Wako Chem USA, Richmond, VA USA
[3] Wako Pure Chem Ind Ltd, Osaka, Japan
来源：
CLINICAL CHEMISTRY | 2005年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：A58 / A58
页数：1
相关论文
共 50 条
  • [1] AFP-L3: a new generation of tumor marker for hepatocellular carcinoma
    Li, D
    Mallory, T
    Satomura, S
    CLINICA CHIMICA ACTA, 2001, 313 (1-2) : 15 - 19
  • [2] Clinical evaluation of AFP-L3: a now tumor marker for aggressive hepatocellular carcinoma.
    Li, DJ
    Henmi, F
    Yamagata, Y
    Nakamura, K
    Mallory, T
    Satomura, S
    CLINICAL CHEMISTRY, 2002, 48 (06) : A19 - A19
  • [3] Clinical utility of AFP-L3% in early detection of hepatocellular carcinoma
    Wang, YY
    Satomura, S
    Wise, M
    Kanke, F
    Mallory, T
    Schwartz, ME
    Sterling, RK
    Jeffers, L
    Gordon, F
    Reddy, RK
    Venook, AP
    Sherman, M
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09): : S122 - S122
  • [4] Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization
    Hiraoka, Atsushi
    Ishimaru, Yoshihiro
    Kawasaki, Hideki
    Aibiki, Toshihiko
    Okudaira, Tomonari
    Toshimori, Akiko
    Kawamura, Tomoe
    Yamago, Hiroka
    Nakahara, Hiromasa
    Suga, Yoshifumi
    Azemoto, Nobuaki
    Miyata, Hideki
    Miyamoto, Yasunao
    Ninomiya, Tomoyuki
    Hirooka, Masashi
    Abe, Masanori
    Matsuura, Bunzo
    Hiasa, Yoichi
    Michitaka, Kojiro
    ONCOLOGY, 2015, 89 (03) : 167 - 174
  • [5] Preliminary study of three tumor markers for hepatocellular carcinoma: AFP, AFP-L3, and Glypican-3
    Li, H.
    Qu, K. Z.
    Ner, R. M.
    Sferruzza, A. D.
    Bender, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis
    Wang, Xueying
    Zhang, Yangyu
    Yang, Na
    He, Hua
    Tao, Xuerong
    Kou, Changgui
    Jiang, Jing
    BIOMED RESEARCH INTERNATIONAL, 2020, 2020
  • [7] AFP-L3 improves AFP performance in the follow up for the development of hepatocellular carcinoma in chronic hepatitis patients
    Antonakis, P.
    Konstadoulakis, M.
    Kataki, A.
    Roayaie, S.
    Schwartz, M.
    ANNALS OF ONCOLOGY, 2006, 17 : 32 - 32
  • [8] Utility of four tumor markers, alone and in combination, for detection of hepatocellular carcinoma: AFP, AFP-L3, DCP, and Cystatin
    Li, H.
    Sferruzza, A.
    Qu, K. Z.
    Afdhal, N. H.
    Lai, M.
    Radcliff, J. S.
    Bender, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] The utility of serum AFP-L3% in the diagnosis of hepatocellular carcinoma: Evaluation in a US referral population
    Leerapun, Apinya
    Suravarapu, V.
    Bida, John P.
    Clark, Raynell J.
    Sanders, Elizabeth L.
    Mettler, Teresa A.
    Stadheim, Linda M.
    Aderca, Ileana
    Moser, Catherine D.
    Nagorney, David M.
    Larusso, Nicholas F.
    de Green, Piet C.
    Menon, K. V. Narayanan
    Lazandis, Konstantinos N.
    Gores, Gregory J.
    Charlton, Michael R.
    Roberts, Rosebud O.
    Themeau, Terry M.
    Katzmann, Jerry A.
    Roberts, Lewis
    GASTROENTEROLOGY, 2006, 130 (04) : A774 - A775
  • [10] Phase 2 validation of AFP, DCP and AFP-L3 in early stage hepatocellular carcinoma
    Marrero, Jorge A.
    Llovet, Josep M.
    Nguyen, Mindie
    Befeler, Alex
    Roberts, Lewis R.
    Reddy, Rajender R.
    Harnois, Denise
    Normolle, Daniel
    Hui, Ying
    Dalhgren, Jackie
    Chia, David
    Lok, Anna S.
    Wagner, Paul D.
    Feng, Ziding
    Schwartz, Myron
    CANCER BIOMARKERS, 2008, 4 (03) : 183 - 183
12345